Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which can lead to death.

According to the International Agency for the Prevention of Blindness 2017, glaucoma is the second leading cause of blindness and leading cause of irreversible blindness, worldwide. The most common types of glaucoma are primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG).The significant risk of developing glaucoma increases with age, increased intraocular pressure, positive family history for glaucoma, and ethnicity.

For instance, according to the American Academy of Ophthalmology’s 2016 report, the global prevalence of glaucoma is estimated to rise to 76 million in 2020 and 111.8 million in 2040.

COVID-19 IMPACT ANALYSIS

The coronavirus pandemic has drastically altered the lives of patients of glaucoma everywhere, and everyone is grappling with changes to health, daily routines, and management of glaucoma during the coronavirus pandemic. According to the World Health Organization Coronavirus Disease (COVID-19) Dashboard (WHO), the manifestation of the coronavirus has resulted in more than 7 million infected individuals worldwide as of June 2020.

According to the Bright Focus Foundation’s data of April 15, 2020, glaucoma is more prevalent in the African American population. African Americans also experience higher prevalence of diabetes and hypertension which makes them especially vulnerable to COVID-19 infection.

The WHO has encouraged ophthalmic drug manufacturing companies to take safety and responsible measures in order to reduce the spread of coronavirus. For instance, limiting the number of people in one area at a time, modifying workstation arrangements, and minimizing the cross flow of people between shifts to reduce potential exposure, along with enhanced cleaning and sanitization of facilities.

The American Academy of Ophthalmology has prudently issued a statement to cease all non-urgent care in the office and all elective surgeries in the operating room to preserve much-needed resources.

Healthcare providers, including ophthalmologists, may be called upon and deployed to the frontline to care for patients infected with COVID-19. Clinics are taking steps to ensure utmost safety for the patients.

The Glaucoma Eye Drops Market is estimated to be valued at US$ 1,360.1 million in 2020 and is expected to exhibit a CAGR of 7.0% during the forecast period (2020-2027).

Figure 1. Global Glaucoma Eye Drops Market Share (%) Analysis, By Drug Type, 2020

Glaucoma Eye Drops  | Coherent Market Insights

The increasing number of product launches and approvals are expected to drive the growth of glaucoma eye drops market.

Several novel glaucoma eye drops have been approved by regulatory bodies in different countries and major players in the market have launched various novel and innovative glaucoma eye drops. Rapid approvals and launches of novel products in the market are expected to be a major driver for growth of the glaucoma eye drops market.

For instance, in March 2019, the U.S. Food and Drug Administration (FDA) approved Aerie Pharmaceuticals' Rocklatan (netarsudil and latanoprost ophthalmic solution) for treatment of open-angle glaucoma or ocular hypertension. Rocklatan is a once-daily eye drop that is a fixed-dose combination of latanoprost, the most widely-prescribed prostaglandin analog (PGA), and netarsudil, the active ingredient in Rhopressa (netarsudil ophthalmic solution) 0.02%. It is a first-in-class Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork.

The glaucoma eye drops market is expected to witness high growth and generate high revenue owing to product launches for the treatment of glaucoma during the forecast period. For instance, in June 16 2020, Senju Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that a new combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE Combination Ophthalmic Suspension (generic name: brimonidine tartrate/brinzolamid), has been launched in Japan. Senju Pharmaceutical Co., Ltd. (marketing authorization holder) and Otsuka Pharmaceutical Co., Ltd. (collaborator) will conduct activities related to the provision of drug information for this drug.

Glaucoma Eye Drops Market - Restraints

However, glaucoma is a disease that cannot be cured, but it can be controlled. Eye drops, pills, laser procedures, and surgical operations are used to prevent or slow further damage from occurring. Glaucoma is an irreversible disease, and the extensive R&D activities make the drug very expensive which is expected to hamper the glaucoma eye drops market growth during the forecast period. For instance, according to data published by the National Center for Biotechnology Information, yearly cost of prostaglandin analogs ranged from US$ 427.69 for Travatan (Alcon) to US$ 577.62 for Lumigan (Allergan). Alphagan P 0.15% had yearly calculated costs of US$ 559.08 for twice daily dosing per eye. Cosopt (Merck & Co.) costs as high as US$ 697.42 to US$ 873.98.

request-sample

Glaucoma Eye Drops Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,360.1 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 7.0% 2027 Value Projection: US$ 2,182.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Prostaglandin analogs, Beta blockers, Alpha agonists, Carbonic Anhydrase Inhibitors (CAIs), Combined Medications, Others (rho-kinase inhibitor, Cholinergic agonist).
  • By Disease Indication: Angle-closure Glaucoma, Open-angle Glaucoma.
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy.
  • By Composition: Preservative Free, BAK-Based, Non BAK-Based Preservatives.
Companies covered:

Merck & Co., Inc., Allergan Plc., Novartis AG., Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.

Growth Drivers:
  • The increasing number of product launches and approvals
  • Increasing robust product pipeline for treatment of glaucoma
Restraints & Challenges:
  • High Cost of Glaucoma Treatment and Availability of Alternatives

Glaucoma Eye Drops Market – Regional Analysis

North America accounted for the largest share in the glaucoma eye drops market in 2019, owing to the increasing number of product launches and approvals of glaucoma eye drops by regulatory bodies. For instance, in November 2017, Bausch + Lomb, a subsidiary of Valeant Pharmaceuticals International, Inc., and Nicox S.A., received U.S. Food and Drug Administration’s approval of the New Drug Disease Indication (NDA) for VYZULTA, indicated for the treatment of open-angle glaucoma.

Furthermore, Asia Pacific is expected to observe the fastest growth during the forecast period. Market players are focusing on various inorganic strategies such as mergers and agreements. For instance, in December 2018, Nicox SA entered an exclusive license agreement with Ocumension Therapeutics for the development and commercialization of NCX 470, an ophthalmic solution, in China, Hong Kong, Macau, and Taiwan.

Figure 2. Global Glaucoma Eye Drops Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Glaucoma Eye Drops  | Coherent Market Insights

Glaucoma Eye Drops Market - Competitive Landscape

Key players operating in the glaucoma eye drops market are Merck & Co., Inc., Allergan Plc. Novartis AG. Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.

Glaucoma may occur among the people with or without diabetes. Moreover, people with diabetic retinopathy have an increased risk of glaucoma. The condition is associated with abnormal blood vessel growth, which can result in retinopathy and leads to blockage of natural drainage of the eye. Rapidly increasing geriatric population is one of the important factors for increasing prevalence of glaucoma, which in turn is projected to drive growth of the glaucoma therapeutics market in near future. For instance, according to the International Diabetes Foundation (IDF) 2017 statistics, the number of people with diabetes aged between 20 to 79 years are increasing worldwide.

Market Dynamics

The global glaucoma eye drops market is expected to witness significant growth during the forecast period owing to the increasing prevalence of glaucoma, For instance, according to the International Agency for the Prevention of Blindness, in 2015, an estimated 3 million people suffered from blindness due to glaucoma in the U.S. Furthermore, as per the same source, it is estimated that by 2020 around 80 million people will suffer from glaucoma, with an increase of about 20 million from 2010 globally.

Key features of the study:

  • This report provides in-depth analysis of the global glaucoma eye drops market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global glaucoma eye drops market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co., Inc., Allergan Plc., Novartis AG., Teva Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The global glaucoma eye drops market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for glaucoma eye drops, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Glaucoma Eye Drops Market, By Drug Type:
    • Prostaglandin analogs
    • Beta blockers
    • Alpha agonists
    • Carbonic Anhydrase Inhibitors (CAIs)
    • Combined Medications
    • Others (rho-kinase inhibitor, Cholinergic agonist)
  • Global Glaucoma Eye Drops Market, By Disease Indication:
    • Angle-closure Glaucoma
    • Open-angle Glaucoma
  • Global Glaucoma Eye Drops Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Glaucoma Eye Drops Market, By Composition:
    • Preservative Free
    • BAK-Based
    • Non BAK-Based Preservatives
  • Global Glaucoma Eye Drops Market, By Region:
    • North America
      • By Country:
        • S.
        • Canada
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
    • Europe
      • By Country:
        • K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Prostaglandin analogs
        • Beta blockers
        • Alpha agonists
        • Carbonic Anhydrase Inhibitors (CAIs)
        • Combined Medications
        • Others (rho-kinase inhibitor, Cholinergic agonist)
      • By Disease Indication:
        • Angle-closure Glaucoma
        • Open-angle Glaucoma
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
      • By Composition:
        • Preservative Free
        • BAK-Based
        • Non BAK-Based Preservatives
  • Company Profiles
    • Merck & Co., Inc.
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Allergan Plc.
    • Novartis AG
    • Teva Pharmaceutical Industry
    • Pfizer, Inc.
    • Bausch & Lomb Inc.
    • Inotek Pharmaceutical
    • Jadran-galenski laboratorij d.d.
    • Aerie Pharmaceutical
    • Mylan N.V

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Composition
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Pipeline Analysis
    • Product Approvals
    • Product Launches
    • Pest Analysis
    • Pricing Analysis
    • Preservative and preservative-free glaucoma treatment solutions
  4. Impact Analysis of Covid-19
    • Supply side Analysis
    • Demand Side Analysis
    • Impact on Healthcare Industry
  5. Global Glaucoma Eye Drops Market, By Drug Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Prostaglandin analogs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Beta blockers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Alpha agonists
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Carbonic Anhydrase Inhibitors (CAIs)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Combined Medications
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others (rho-kinase inhibitor, Cholinergic agonist)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Glaucoma Eye Drops Market, By Disease Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Angle-closure Glaucoma
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Open-angle Glaucoma
      • Introduction
      • Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Glaucoma Eye Drops Market, By Distribution Channel , 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Glaucoma Eye Drops Market, By Composition, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Preservative Free
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • BAK-Based
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Non BAK-Based Preservatives
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  9. Global Glaucoma Eye Drops Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel , 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Composition, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
  10. Competitive Landscape
    • Company Profiles
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Allergan Plc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industry
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bausch & Lomb Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Inotek Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Jadran-galenski laboratorij d.d.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Aerie Pharmaceutical
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 28 figures on "Global Glaucoma Eye Drops Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the Glaucoma Eye Drops Market is expected to be 7.0% during the forecast period (2020-2027).
The value of Glaucoma Eye Drops Market is estimated to be US$ 1,360.1 million in 2020.
The prominent players in the global Glaucoma Eye Drops Market are Merck & Co., Inc., Allergan Plc., Novartis AG., Pharmaceutical Industry, Pfizer, Inc., Bausch & Lomb Inc., Inotek Pharmaceutical, Jadran-galenski laboratorij d.d., Aerie Pharmaceutical, and Mylan N.V.
The Glaucoma Eye Drops Market is expected to be valued at US$ 2,182.3Mn in 2027.
North America is the major region in the Glaucoma Eye Drops Market.
The increasing number of product launches and approvals and robust product pipeline for treatment of glaucoma.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner